BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, November 29, 2023
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Carrick receives US IND approval for CDK12/13 inhibitor CT-7439 for advanced solid tumors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Carrick receives US IND approval for CDK12/13 inhibitor CT-7439 for advanced solid tumors
Sep. 8, 2023
No Comments
Carrick Therapeutics Ltd. has received FDA clearance of its IND application for CT-7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.
BioWorld Science
Regulatory
Cancer
FDA
IND
